XOMA Corporation (XOMA)
| Bid | 18 |
| Market Cap | 279.22M |
| Revenue (ttm) | 22.11M |
| Net Income (ttm) | -13.82M |
| EPS (ttm) | -1.65 |
| PE Ratio (ttm) | -14.16 |
| Forward PE | 80.8 |
| Analyst | Buy |
| Ask | 29 |
| Volume | 26,020 |
| Avg. Volume (20D) | 26,803 |
| Open | 22.95 |
| Previous Close | 24.04 |
| Day's Range | 22.80 - 23.50 |
| 52-Week Range | 18.35 - 35.00 |
| Beta | 1.00 |
About XOMA
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with ...
Analyst Forecast
According to 3 analyst ratings, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is $74, which is an increase of 216.78% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · accessnewswire.com
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...
